biostudies-literatureUnknownAbuknesha NRNIA NIH HHSNHLBI NIH HHS<h4>Background</h4>Recent meta-analyses of randomized controlled trials (RCTs) have raised concerns that treatment with omega-3 fatty acids may increase risk of atrial fibrillation (AF). However, these meta-analyses included at most eight trials. The aim of this current meta-analysis was to expand the search by including other eligible omega-3 RCTs with AF incidence data, incorporating both published and unpublished data.<h4>Methods</h4>Eligible studies were RCTs investigating daily doses of ≥500 mg/d of docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA). Additional inclusion criteria included ≥12 months treatment with EPA/DHA, participants ≥ 50 years of age, and where possible, the absence of known AF/atrial flutter at baseline. The primary outcome was occurrence of new-onset AmedRxiv : the preprint server for health sciences2025.12.14.25342167https://www.ebi.ac.uk/biostudies/studies/S-EPMC12723971biostudies-literatureEffects of Omega-3 Fatty Acid Treatment on Risk for Atrial Fibrillation: An Updated Meta-Analysis of 34 Trials including 114,326 Individuals.PMC12723971T32 HL125232U19 AG010483Chew EYLan THSchoenfeld DAWelty FKSu KPTintle NLHarris WSMengelberg AYusuf SVan Hulle CAAbuknesha NRLin YVauzour DCohen NJLiddell ABudoff MJSanders TABFezeu LKGalan PBurns NRAisen PSBischoff-Ferrari HAvan Dyck CHCardenas CAQian HZAsbeutah AAAO'Keefe JHQian FWeber CAronson WJAlbert CMCarlsson CMHull MASun YLin PYQuinn JFMinihane AMSprange KWittert GScholey AfalseEffects of Omega-3 Fatty Acid Treatment on Risk for Atrial Fibrillation: An Updated Meta-Analysis of 34 Trials including 114,326 Individuals.<h4>Background</h4>Recent meta-analyses of randomized controlled trials (RCTs) have raised concerns that treatment with omega-3 fatty acids may increase risk of atrial fibrillation (AF). However, these meta-analyses included at most eight trials. The aim of this current meta-analysis was to expand the search by including other eligible omega-3 RCTs with AF incidence data, incorporating both published and unpublished data.<h4>Methods</h4>Eligible studies were RCTs investigating daily doses of ≥500 mg/d of docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA). Additional inclusion criteria included ≥12 months treatment with EPA/DHA, participants ≥ 50 years of age, and where possible, the absence of known AF/atrial flutter at baseline. The primary outcome was occurrence of new-onset A2025-01-01T00:00:00Z2025 Dec2026-07-05T03:11:48.132Z2026-07-05T03:08:32.154ZS-EPMC127239714144562410.64898/2025.12.14.25342167